Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Cumulative incidence of false-positive results in repeated, multimodal cancer screening.

Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG, Fagerstrom R, Riley TL, Clapp JD, Berg CD, Gohagan JK, Andriole GL, Chia D, Church TR, Crawford ED, Fouad MN, Gelmann EP, Lamerato L, Reding DJ, Schoen RE.

Ann Fam Med. 2009 May-Jun;7(3):212-22. doi: 10.1370/afm.942.

2.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team.

J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6.

3.

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team.

JAMA. 2011 Jun 8;305(22):2295-303. doi: 10.1001/jama.2011.766.

PMID:
21642681
4.

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.

Gohagan JK, Prorok PC, Hayes RB, Kramer BS; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.

Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S.

PMID:
11189683
5.

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.

Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S.

PMID:
11189684
6.

Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination.

Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Doria-Rose VP, Laiyemo AO, Church T, Yokochi LA, Yurgalevitch S, Rathmell J, Andriole GL, Buys S, Crawford ED, Fouad M, Isaacs C, Lamerato L, Reding D, Prorok PC, Berg CD; PLCO Project Team.

J Natl Cancer Inst. 2012 Feb 22;104(4):280-9. doi: 10.1093/jnci/djr549. Epub 2012 Jan 31.

7.

Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Weissfeld JL, Fagerstrom RM, O'Brien B; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.

Control Clin Trials. 2000 Dec;21(6 Suppl):390S-399S.

PMID:
11189690
8.

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C.

Clin Trials. 2010 Aug;7(4):303-11. doi: 10.1177/1740774510374091. Epub 2010 Jun 22.

PMID:
20571134
9.

Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial.

Croswell JM, Baker SG, Marcus PM, Clapp JD, Kramer BS.

Ann Intern Med. 2010 Apr 20;152(8):505-12, W176-80. doi: 10.7326/0003-4819-152-8-201004200-00007. Erratum in: Ann Intern Med. 2010 Jun 1;152(11):759.

PMID:
20404381
10.

Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.

PMID:
23440794
11.

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.

Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK; PLCO Project Team.

J Natl Cancer Inst. 2005 Mar 16;97(6):433-8.

PMID:
15770007
12.

Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Andriole GL.

Recent Results Cancer Res. 2014;202:53-7. doi: 10.1007/978-3-642-45195-9_6.

PMID:
24531777
13.

Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.

Nyante SJ, Black A, Kreimer AR, Duggan MA, Carreon JD, Kessel B, Buys SS, Ragard LR, Johnson KA, Dunn BK, Lamerato L, Commins JM, Berg CD, Sherman ME.

Gynecol Oncol. 2011 Mar;120(3):474-9. doi: 10.1016/j.ygyno.2010.11.015. Epub 2010 Dec 7.

14.

The economic impact of false-positive cancer screens.

Lafata JE, Simpkins J, Lamerato L, Poisson L, Divine G, Johnson CC.

Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2126-32.

15.

Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.

Pinsky PF, Andriole GL, Kramer BS, Hayes RB, Prorok PC, Gohagan JK; Prostate, Lung, Colorectal and Ovarian Project Team.

J Urol. 2005 Mar;173(3):746-50; discussion 750-1.

PMID:
15711261
16.

False-positive cancer screens and health-related quality of life.

McGovern PM, Gross CR, Krueger RA, Engelhard DA, Cordes JE, Church TR.

Cancer Nurs. 2004 Sep-Oct;27(5):347-52.

PMID:
15525861
17.

Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial.

Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Church T, Yurgalevitch S, Austin JH, Prorok PC, Gohagan JK; PLCO Project Team.

J Natl Cancer Inst. 2005 Jul 6;97(13):989-97.

PMID:
15998952
18.

Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials.

O'Grady TJ, Kitahara CM, DiRienzo AG, Boscoe FP, Gates MA.

PLoS One. 2014 Sep 5;9(9):e106880. doi: 10.1371/journal.pone.0106880. eCollection 2014.

19.

Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial.

Taylor KL, Shelby R, Gelmann E, McGuire C.

J Natl Cancer Inst. 2004 Jul 21;96(14):1083-94.

PMID:
15265970
20.

Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Oken MM, Marcus PM, Hu P, Beck TM, Hocking W, Kvale PA, Cordes J, Riley TL, Winslow SD, Peace S, Levin DL, Prorok PC, Gohagan JK; PLCO Project Team.

J Natl Cancer Inst. 2005 Dec 21;97(24):1832-9.

PMID:
16368945

Supplemental Content

Support Center